Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$309K Buy
2,408
+403
+20% +$47.2K 0.11% 101
2026
Q1
$241K Sell
2,005
-200
-9% -$23.1K 0.1% 93
2025
Q4
$232K Buy
+2,205
New +$207K 0.09% 87
2025
Q2
Sell
-2,660
Closed -$239K 91
2025
Q1
$239K Sell
2,660
-18
-0.7% -$1.68K 0.13% 79
2024
Q4
$266K Buy
2,678
+100
+4% +$10.3K 0.13% 74
2024
Q3
$293K Hold
2,578
0.15% 71
2024
Q2
$319K Buy
2,578
+210
+9% +$27.1K 0.17% 63
2024
Q1
$312K Hold
2,368
0.17% 65
2023
Q4
$258K Hold
2,368
0.16% 63
2023
Q3
$244K Hold
2,368
0.19% 61
2023
Q2
$273K Hold
2,368
0.2% 59
2023
Q1
$252K Sell
2,368
-82
-3% -$8.85K 0.22% 55
2022
Q4
$272K Buy
2,450
+82
+3% +$8.38K 0.28% 50
2022
Q3
$204K Sell
2,368
-100
-4% -$8.93K 0.2% 57
2022
Q2
$225K Buy
+2,468
New +$219K 0.2% 57
2021
Q1
Sell
-2,596
Closed -$203K 74
2020
Q4
$203K Sell
2,596
-574
-18% -$43.9K 0.17% 70
2020
Q3
$251K Buy
3,170
+424
+15% +$33.2K 0.24% 61
2020
Q2
$203K Sell
2,746
-52
-2% -$3.92K 0.21% 61
2020
Q1
$205K Sell
2,798
-112
-4% -$8.8K 0.29% 51
2019
Q4
$253K Buy
+2,910
New +$239K 0.25% 67

Other funds holding MRK

Bay Rivers Group's MRK Position: Q2 2026 in Review

Bay Rivers Group increased its Merck (MRK) stake by 20% in Q2 2026, buying an estimated $47.2K and bringing the position to 2,408 shares worth $309K. The position accounts for 0.11% of the portfolio, ranked #101.

Bay Rivers Group first reported a position in MRK in Q4 2019 and has held it in 20 quarters since. The position peaked at $319K in Q2 2024. 1,627 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Bay Rivers Group held 2,408 shares of Merck worth $309K as of Q2 2026.
  • Bay Rivers Group bought 403 Merck shares in Q2 2026, an estimated $47.2K.
  • Merck made up 0.11% of Bay Rivers Group's portfolio in Q2 2026, its #101 holding.
  • Bay Rivers Group first reported a position in Merck in Q4 2019 and has held it in 20 quarters since.
  • Bay Rivers Group's Merck position peaked at $319K in Q2 2024.
  • 1,627 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Bay Rivers Group's 13F filing for Q2 2026, filed 9 Jul 2026.